Asthma Clinical Trial
Official title:
Predicting the Diagnosis of Asthma Based on History
Despite the development of effective medications for treatment, asthma remains a significant
contributor of morbidity, mortality, and financial hardship to patients with the disease. An
estimated 300 million people worldwide have asthma, making it one of the most common chronic
diseases in the world. Asthma accounts for 250,000 deaths per year worldwide, and 1.7
million emergency room visits per year in the United States. Cost of asthma in the United
States was an estimated $12.7 billion dollars per year in 1998, and the prevalence is
increasing. In 2002, there were 13.9 million outpatient asthma visits to private physician
offices and hospital outpatient departments, and 484,000 asthma hospitalizations. Children
5-17 years of age missed 14.7 million school days, and adults missed 11.8 million work days
due to asthma in 2002.
There is no single diagnostic test or symptom that defines asthma. Asthma is a syndrome
consisting of a constellation of symptoms that include wheeze, cough, shortness of breath,
and chest tightness. The diagnosis of asthma takes into account history, physical
examination findings, and objective measures of pulmonary function and markers of
inflammation. In many cases the diagnosis is not in question, allowing for early recognition
and appropriate treatment. In other cases, confounding factors makes the diagnosis both
challenging and time consuming for the physician and the patient. According to the National
Asthma Education and Prevention Program Expert Panel Report 2, asthma is defined as:
"a chronic inflammatory disorder of the airways in which many cells and cellular elements
play a role, in particular, mast cells, eosinophils, T lymphocytes, macrophages,
neutrophils, and epithelial cells. In susceptible individuals, this inflammation causes
recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly
at night or in the early morning. These episodes are usually associated with widespread but
variable airflow obstruction that is often reversible either spontaneously or with
treatment. The inflammation also causes an associated increase in the existing bronchial
hyperresponsiveness to a variety of stimuli."
Airway obstruction and reversibility is measured by pulmonary function testing before and
after inhalation of a short acting beta agonist. Airway hyperresponsiveness is measured by
methacholine challenge.
Estimates of asthma prevalence are generated by the use of written questionnaires in
epidemiologic studies. , One of the difficulties with reliance on questionnaires is that
patients often misinterpret the questions or fail to answer the question altogether. In this
study, a physician will review the questionnaire with the patient in order to clarify each
question.
The goal in this study is to evaluate a simplified set of questions that can be easily
implemented into clinical practice that will predict the presence or absence of asthma.
Hypothesis
A simplified questionnaire will predict asthma in adults.
Study Objectives
§ Primary Objective
o To evaluate the predictive value of a questionnaire designed to diagnose asthma in adults
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|